55.80
+4.05%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genmab AS
Its shares trade under the ticker GMAB. It has been listed since 1 June 2009. In the fiscal year to 31 December 2025, it reported revenue of $3.72bn and net income of $963.8m. At that date it held total assets of $12.84bn and shareholders' equity of $5.83bn.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Jun 2009
- Employees
- 3,029
- Website
- genmab.com ↗
- Head office
- TOLDBODGADE 33, 1253 COPENHAGEN K, G7, 00000
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genmab AS develops antibody-based products for cancer treatment in Denmark.
- EPKINLY and TEPKINLY are marketed for R/R DLBCL and follicular lymphoma.
- Tivdak is approved for recurrent/metastatic cervical cancer after chemotherapy.
Weaknesses
- Genmab AS has 3029 employees in Copenhagen, Denmark.
- The company is listed on the stock market since 1 June 2009.
- Genmab AS operates in the Health Care sector with limited product diversity.
Opportunities
- Epcoritamab is in development for R/R DLBCL and FL in first line treatment.
- Tisotumab vedotin targets solid tumors with potential market expansion.
- Acasunlimab is being developed for solid tumors and NSCLC in clinical trials.
Threats
- Rinatabart Sesutecan is in development for platinum resistant ovarian cancer.
- GEN1059, GEN1055, and GEN1057 target solid tumors with competitive markets.
- GEN1286 is in development for advanced solid tumors with high R&D costs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.